科室专家
个人简历
社会任职：
北京药理学会药物代谢专业委员会委员
《现代药物与临床》青年编委
《中国临床药理学杂志》青年编委
个人简介：
1. 教育背景
2002.09 ~ 2007.06 河北医科大学，临床医学系，医学学士
2007.09 ~ 2010.06 上海交通大学，医学免疫学，医学硕士2012.09 ~ 2015.06 复旦大学，药理学，理学博士
2. 工作经历
2010.07 ~ 2017.09 上海市徐汇区中心医院, I期临床试验研究室
2017.11 ~ 2019.12 首都医科大学宣武医院，药物研究室，药理学博士后
2020.01 ~至今 首都医科大学宣武医院，药学部，I期临床研究中心
3. 科研水平
主要从事药物早期临床试验研究工作，作为助理研究者完成I期临床试验和生物等效性试验100余项，作为主要研究者5项;对创新药物的安全耐性研究、药代动力学和药效学研究、食物影响和物料平衡试验、药物-药物相互作用研究、以及仿制药的生物等效性研究，在方案设计、试验实施和质量管理方面具有丰富的实践经验。
作为负责人获批5项课题，其中国家级1项、省部级1项、局级2项和院级课题1项;入选2020年度北京市医院管理中心青苗计划;以第一作者和共同第一作者发表SCI论文12篇，参与发表核心期刊论文50余篇。
主持课题：
1) 国家自然科学基金青年项目，81903880，基于NLRP3炎性小体调控机制探讨淫羊藿苷调节小胶质细胞表型极化抑制多发性硬化免疫炎症反应的研究，2020/01-2022/12，20万，在研;
2) 中国博士后基金，2019M650776，AGC调节TLR4/9信号通路抑制IS炎症反应的作用机制研究, 2019/01-2019/11，8万元，结题;
3) 北京市博士后科研活动经费，2018-ZZ-105，痘苗病毒致炎兔皮提取物治疗缺血性脑卒中的机制研究，2018/06-2019/11，10.3万元，结题;
4) 上海市徐汇区卫生局青年项目，SHXH201140，LC-MS/MS法测定维生素E醋酸酯检测平台的建立及临床应用研究，2012/01-2014/12，3万，结题;
5) 上海市徐汇区中心医院科研基金重点项目，2011XHCH07，γδ T细胞与类风湿性关节炎发病关联性研究，2011/05-2014/04，5万，结题;
发表SCI论文：
1) Hu Chaoying, Ji bingxin, Hu Xiao, et al. Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study[J]. Clinical Pharmacology in Drug Development. 2021; 10(3):291-298.
2) Hu Chaoying, Lin Qingtang, Liu Chuan, et al. Bioequivalence study of 20-mg and 100-mg temozolomide capsules (TOZ309 and Temodal ®) in glioma patients in China[J]. Cancer Chemother Pharmacol. 2020; 86(6):793-801.
3) Hu Chaoying, Chen xiaoping, Zhao Zirun, et al. A Two-Sequence, Four-Period, Crossover, Replicate Study to Demonstrate Bioequivalence of Warfarin Sodium Tablet in Healthy Chinese Subjects Under Fasting and Fed Conditions[J]. Clinical Pharmacology in Drug Development. 2020; 9(4) 527-536.
4) Wang Chunhua&, Hu Chaoying&, Gao Dan et al. Pharmacokinetics and bioequivalence of generic and branded abiraterone acetate tablet: a single-dose, open-label, and replicate designed study in healthy Chinese male volunteers [J]. Cancer Chemother Pharmacol. 2019; 83:509–517.
5) Hu Chaoying, Hu Xiao, Wang Chunhua, et al. Bioequivalence and Pharmacokinetics of Bisoprolol Amlodipine 5 mg/5 mg Combination Tablet versus Bisoprolol 5 mg Tablet and Amlodipine 5 mg Tablet: an open-label, randomized, two-sequence crossover study in Chinese healthy subjects[J]. Clinical Drug Investigation. 2018; 38(12):1145-1154.
6) Hu Chaoying, Yijun Wang, Rong Song, et al. Single- and Multiple-dose Pharmacokinetics of Lurasidone in Healthy Chinese Subjects [J]. Clinical Drug Investigation. 2017; 37(9):861-871.
7) Hu Chaoying, Debbie Tompson, Mindy Magee, et al. Single and Multiple Dose Pharmacokinetics, Pharmacodynamics and Safety of the Novel Lipoprotein-Associated Phospholipase A2 Enzyme Inhibitor Darapladib in Healthy Chinese Subjects: An Open Label Phase-1 Clinical Trial [J]. PLOS ONE, 2015; 10(10): e0139862.
8) Hu Chaoying, Jia Jingying, Kelly Dong, et al. Pharmacokinetics and Tolerability of Inhaled Umeclidinium and Vilanterol Alone and in Combination in Healthy Chinese Subjects: A Randomized, Open-Label, Crossover Trial [J]. PLOS ONE, 2015; 10(3): e0121264.
9) Liu Yun&, Hu Chaoying&, Li Gangyi, et al. A Replicate Designed Bioequivalence Study To Compare Two Fixed-Dose Combination Products of Artesunate and Amodiaquine in Healthy Chinese Volunteers [J]. Antimicrob Agents Chemother, 2014; 58(10):6009-6015.
10) Hu Chaoying, Liu Yanmei, Liu Yun, et al. Pharmacokinetics and Tolerability of Tenofovir Disoproxil Fumarate 300 mg Once Daily: An Open-Label, Single- and Multiple-Dose Study in Healthy Chinese Subjects [J]. Clinical Therapeutics, 2013; 35(12):1884-1889.
11) Hu Chaoying&, Qian Liu&, Miao Yi, et al. Antigen-presenting effects of effector memory Vγ9Vδ2 T cells in rheumatoid arthritis [J]. Cell Mol Immunol, 2012; 9(3):245-254.
12) Wang Yuan&, Hu Chaoying&, Dong Ruofan, et al. Platelet-derived growth factor-D promotes ovarian cancer invasion by regulation matrix metalloproteinases 3 and 9 [J]. Asian Pacific Journal of Cancer Prevention, 2011; 12(12):3367-3370.
